血小板保养液与血浆混合保存血小板的初步研究

目的探讨血小板保养液与不同比例血浆混合保存单采血小板的效果。方法选用枸橼酸钠、醋酸钠、磷酸钠和氯化钠等组成血小板保养液,(22±2)℃振荡条件下保存单采血小板7d;按保养液与血浆混合比例,实验组分为实验Ⅰ组(50%保养液+50%血浆)和实验Ⅱ组(80%保养液+20%血浆),分别于1、3、5、7d取样检测血小板数(Plt)、pH值、葡萄糖消耗量、乳酸产生量和血小板膜CD62p的表达情况,并与100%血浆保存的血小板(对照组)比较。结果血小板保存到5d时,实验组与对照组比较Plt差异无统计学意义(P>0.05),其pH值较对照组均有明显下降(P<0.05),但pH仍>6.0;实验组血小板膜CD62p阳性表达率分别为32%和36%,比对照组的28%略高(P<0.05)。血小板保存到第7天时,Plt、pH和血小板膜CD62p阳性表达率,实验各组较对照组为差(P<0.05);1—7d葡萄糖平均消耗量实验Ⅱ组比对照组和实验Ⅰ组为高(P<0.05),而乳酸平均产生量则实验各组较对照组明显为高(P<0.05)。结论采用血小板保养液与20%或50%比例的血浆混合,短期(5d)保存单采血小板的pH值和血小板数量与用100%血浆保存单采血小板的效果基本相同,但保存在保养液与血浆混合液中的血小板更易激活。     

混合浓缩血小板在1种国产一次性滤除白细胞血小板贮存袋中保存质量研究

目的考察浓缩血小板混合后在一次性滤除白细胞血小板贮存袋保存过程中的质量变化。方法采用富血小板血浆法(PRP法)从400 mL新鲜全血制备浓缩血小板,将10-12 U(1 U约30 mL)ABO血型同型的浓缩血小板混合并滤除白细胞后,注入一次性滤除白细胞血小板贮存袋振荡保存,共完成10例(袋);分别于滤除白细胞前、后以及保存d1、d3、d5、d7观察涡流现象,检测pH值、血细胞计数、血小板聚集、血小板低渗休克(HSR)、血小板形变能力(ESC),CD62p阳性表达率、血小板ATP含量、葡萄糖和乳酸含量等指标。结果 1个成人治疗剂量的混合浓缩血小板滤除白细胞后血小板回收率(86.7±1.6)%,HSR(3.87±12.75)%,剩余白细胞数(0.15±0.15)×106个,滤除白血病前、后血小板pH值、HSR(%)和CD62p阳性率(%)分别为7.00±0.17 vs 7.06±0.16、66.96±12.35 vs 63.22±8.26、28.94±14.25 vs 31.60±16.77,花生四烯酸诱导时的聚集率(%)106.2±23.5 vs 106.5±20.1,ADP+肾上腺素诱导时的聚集率(%)104.8±19.0 vs 106.5±18.6(P0.05)。随着保存时间的延长,混合浓缩血小板的各项指标绝对值发生变化:保存d1及d5(有效保存期末)的pH值、HSR(%)、CD62p(%)及ESC(%)分别为7.27±0.12 vs 7.13±0.21、62.28±6.93 vs 65.53±8.23、30.27±9.06 vs 34.45±14.23、14.28±2.01 vs 8.55±4.12,花生四烯酸诱导时的聚集率(%)92.2±6.1 vs 86.3±23.1,ADP+肾上腺素诱导时的聚集率(%)为93.2±6.7 vs 44.5±41.6。ATP(μmol/1011个血小板)、乳酸(mmol/L)、葡萄糖(mmol/L)分别为5.40±1.66 vs 4.97±1.01、8.35±2.94 vs 13.87±2.97、24.55±1.53vs 20.75±2.04。结论浓缩血小板经混合、滤除白细胞后放入一次性滤除白细胞血小板贮存袋中保存,保存过程中其质量符合国家标准,可以作为临床单采血小板的补充。     

2种血小板保存袋保存效果的比较

目的比较国产和同类进口产品保存血小板保存袋对机采血小板的保存效果。方法机采血小板无菌加入到2种血小板保存袋于22℃保存,分别在0、3、5和7 d取样品测定血小板聚集功能、膜蛋白CD62p、血小板代谢功能、pH、浓度、MPV、PDW、血小板低渗休克反应(HSR)及细菌培养。结果 2种血小板保存袋常温条件下保存的血小板各项检测指标差异无统计学意义。结论产品保存血小板保存袋相比,各项检测指标差异无统计学意义,2种保存袋保存效果基本一致。     

流行性出血热患者血小板及其参数变化的观察

目的探讨流行性出血热(EHF)患者不同发病期血小板及其参数变化特点。方法用Sysmex F-820型血细胞计数仪对110例EHF患者的血小板(PLT)计数、平均血小板体积(MPV)、血小板体积分布宽度(PDW)三项指标进行动态观察。结果EHF患者发病期PLT呈不同程度减低,PLT(15.0～70.0)×109/L,而MPV、PDW则显著大于对照组(P<0.05);恢复期PLT、MPV、PDW均接近正常水平。结论血小板参数变化特点可作为评价EHF患者趋向康复的一个指标,对临床病情判断及治疗具有重要参考价值。     

M-sol血小板保存液对血小板体外保存期间质量的影响

目的探讨M-sol血小板添加液对保存期血小板质量的影响。方法采集健康献血者标本5份,制备浓缩血小板,应用M-sol血小板添加液保存浓缩血小板,以富含血小板的血浆(血浆组)作对照,分别在保存1、5、7、10d检测血小板计数、平均血小板体积(MPV)、胶原诱导的聚集反应及葡萄糖消耗和乳酸生成。结果 M-sol保存组血小板溶液的pH、pCO2比血浆组稳定,血小板聚集率下降幅度比血浆组小,葡萄糖消耗和乳酸生成幅度低于血浆组。结论 M-sol添加液在血小板的体外保存期维持血小板质量的作用优于血浆。     

乙肝患者血小板参数与肝纤维化的关系

目的:研究肝纤维化患者血小板参数与肝组织纤维增生的关系。方法:选择慢性乙肝肝纤维化患者166例为实验组,乙肝病毒携带者36例为对照组,均经肝组织病理确诊。检测血浆血小板计数(PLT)、平均血小板体积(MPV)、血小板分布宽度(PDW)。结果:实验组PLT随纤维化进展逐步下降,二者呈负相关(rs=-0.835,P<0.001),各分期间差异有显著性(P<0.001);MPV、PDW均与纤维化分期相关(rs=0.436、0.231),MPV均高于对照组,在S1、S2、S3之间差异有显著性(P<0.05),PDW仅S4高于对照组,与S1、S2、S3比较差异有显著性(P<0.05)。结论:PLT与肝纤维化分期呈负相关,PLT<150×109/L,存在明显纤维化,PLT低于正常存在早期肝硬化。MPV、PDW均与肝纤维化分期呈正相关。     

血小板相关参数检测在脑梗死发病中的意义

目的探讨血小板相关参数的检测在脑梗死患者中的变化规律。方法利用流式细胞仪,Advance血凝仪,CoulterSTKS血球仪对60例脑梗死患者治疗前同时进行血小板计数(PLT),血小板平均体积(MPV),血小板分布宽度(PDW),血小板膜糖蛋白(CD62P、CD63),血小板压积(PCT),纤维蛋白原(Fg)检测,并与同年龄段60例正常体检血标本血小板相关参数作为对照组,与脑梗死组进行比较。结果脑梗死患者的PLT、MPV、PDW、CD62P、CD63、PCT、Fg分别是155.73±62.49,9.78±1.56,17.09±0.76,6.24±6.08,6.78±6.17,0.15±0.05,408.20±133.50。MPV、PDW、CD62P、CD63、PCT、Fg较对照组有显著差异(p<0.05)。结论血小板相关参数的检测结果与对照组在统计学上具有显著差异,提示对脑梗死的发病具有一定的相关性。     

PASⅢM血小板保存添加液对保存期血小板质量的影响

目的:探讨PASⅢM血小板保存添加液对保存期血小板质量的影响。方法:采集正常献血者标本15份,制备浓缩血小板。应用PASⅢM血小板保存添加液保存浓缩血小板(PASⅢM保存组),富含血小板的血浆作对照(血浆组)。分别在保存1、5、7、10d,检测血小板计数、平均血小板体积(MPV)、胶原诱导的聚集反应、血小板活化率及葡萄糖消耗和乳酸生成。结果:PASⅢM保存组血小板溶液的pH、pCO2和MPV比血浆组稳定。血小板活化率在血浆组随保存时间上升,在PASⅢM保存组比较稳定。血小板聚集率在PASⅢM保存组比血浆组下降幅度小。PASⅢM保存组葡萄糖消耗和乳酸生成幅度低于血浆组。结论:PASⅢM保存添加液在血小板的体外保存期维持血小板质量的作用上优于血浆。     

保存期内单采血小板体外特性的初步研究

目的探讨保存期间不同含量和纯度的单采血小板体外特性的变化。方法根据血小板的含量和纯度,将单采血小板分为Ⅰ组、Ⅱ组和Ⅲ组,(22±2)℃震荡条件下,100%血浆保存7 d,分别于d 0、d 1、d 5、d 7取样检测血小板数(Plt)、血小板形态、pH、葡萄糖、乳酸含量、CD62p、血小板聚集功能(PAgT)和细菌培养等指标。结果血小板保存到d 7时,各组乳酸生成量、MPV、CD62p阳性表达率显著增加,pH、PAgT显著降低(P<0.05),但Ⅱ组各项指标的变化程度比Ⅰ、Ⅲ组低,且pH仍>6.7;与d 5相比,Ⅱ组血小板的新陈代谢指标、形态学、活化与体外功能指标并无统计学差异(P>0.05),亦未见细菌生长。结论在血小板保存过程中,确实存在保存损伤,不同含量和纯度的血小板制品损伤程度不一,只要将每袋血小板计数控制在(1.0—5.0)×1011,白细胞污染率控制在1.0×106以下,可以将保存时间由目前的d 5延长到d 7。     

急性脑梗死血小板相关参数的改变

目的 研究急性脑梗死患者治疗前后血小板相关参数的变化.方法 以本院住院的67例急性脑梗死患者为研究对象,利用流式细胞仪、Coulter STKS血球仪同时进行血小板计数(PLT)、血小板平均体积(MPV)、血小板分布宽度(PDW)、血小板膜糖蛋白(CD62P、CD63)、血小板比容(PCT)检测,观察治疗前后血小板相关参数的变化.结果 脑梗死患者治疗前的PLT、MPV、PDW、CD62P、CD63、PCT分别是(155.73±54.73)× 109/L,(9.56±0.27)fl,(16.24±0.35)%,(6.24±3.79)%,(6.23±3.54)%,(0.15±0.07)%;治疗后分别是(175.45±62.49)×109/L,(9.16±0.64)fl,(17.03±0.67)%,(0.98±0.57)%,(2.25±1.50)%,(0.16±0.02)%.MPV、PDW、CD62P、C1363、PCT治疗前后差异有统计学意义(P＜0.05).结论 血小板相关参数的检测结果治疗前后差异有统计学意义,提示与脑梗死的发病具有一定的相关性.     

不同比例血浆对GMA添加液4℃保存血小板体外质量的影响

目的分析低温液态条件下血浆对保存于葡萄糖甘露醇腺嘌呤（GMA）血细胞添加液中血小板体外质量的影响。方法取白膜法制备的浓缩血小板（PCs）7单位。每单位等分成3份,分离部分血浆后,按比例加入GMA血细胞添加液,制成10％血浆-PCs、35％血浆-PCs和100％血浆-PCs,置4℃冷藏5d。检测0d和5d的血小板计数、pH、平均血小板体积（MPV）、血小板低渗休克反应（HSR）、血小板形变能力（ESC）、P-选择素（P—selectin）、磷脂酰丝氨酸（PS）、血小板表面糖蛋白GPIbα以及乳酸和RANTES（Regulated On Activation,Normal,T—cell Expressed,and Secreted）的生成。结果4℃冷藏5d后,35％血浆-PCs与100％血浆-PCs比较,血小板计数、pH、MPV、HSR、P—selectin、GPIbα和PS以及乳酸和RANTES的差异无显著性（P〉0．05）;而10％血浆-PCs与35％血浆-PCs和100％血浆-PCs比较,P—selectin和PS表达的增加,差异有显著性（P〈0．05）,而HSR下降,但差异无显著性（P=0．09）;10％血浆-PCs与100％血浆-PCs比较,血小板计数下降,乳酸的生成增加,差异有显著性（P〈0．05）。结论用GMA保存液4℃保存血小板时,35％ACD血浆可维持冷藏血小板的膜的完整性、正常代谢和功能。     

Buffy-coat platelet variables and metabolism during storage in additive solutions or plasma

BACKGROUND: Buffy-coat processing allows for the use of platelet additive solutions (PASs). PASs reduce plasma-associated transfusion reactions and conserve plasma for transfusion or fractionation. Platelet (PLT) storage in plasma was compared to storage in three commercially available PASs compared to assess their influence on in vitro laboratory variables. STUDY DESIGN AND METHODS: Platelet concentrates (PCs) were prepared from leukoreduced pools of four buffy coats (BCPs) suspended in autologous plasma or one of PASs (Composol, Fresenius-Kabi; T-Sol, Baxter Corp.; or SSP+, MacoPharma). On Days 1, 2, 3, 5, and 7 of storage, samples were tested for PLT concentration, mean PLT volume (MPV), CD62P, morphology, pO2, pCO2, glucose, lactate and total protein concentration, pH, extent of shape change (ESC), and hypotonic shock response (HSR). Data were analyzed by analysis of variance (ANOVA) with repeated measures and t tests. RESULTS: PLT recoveries from BCPs were higher (p < 0.05) with plasma than any PAS. Storage medium and duration did not affect PLT concentration or MPV over time. CD62P expression and morphology were significantly different among PCs pooled with different media. ANOVA showed (p < 0.05) differences among the rates of change of pCO2, pH, glucose consumption, lactate production, and ESC; PASs such as Composol and SSP+ offered excellent maintenance of pH and low rates of glucose consumption. PAS performed poorly in ESC and HSR compared to plasma. Correlation studies reveal far more significant correlations between variables of PLTs in PAS than in plasma. CONCLUSION: Newer PASs, for example, SSP+ and Composol, can maintain PLT integrity and moderate metabolism similarly to plasma but offer consistently lower PLT recoveries and limited osmotic balance.     

In vitro variables of apheresis platelets are stably maintained for 7 days with 5% residual plasma in a glucose and bicarbonate salt solution, PAS-5

BACKGROUND: Platelet additive solutions (PASs) facilitate improved recovery of plasma and may reduce the severity and/or frequency of plasma‐associated transfusion reactions. Current apheresis platelet (PLT) PAS products contain approximately 30 to 40% residual plasma. In an effort to further decrease the residual plasma, two in vitro studies were conducted with PLTs suspended in 5% plasma and a reformulated PAS‐3, named PAS‐5, that contains additional salts, glucose, and bicarbonate. STUDY DESIGN AND METHODS: In Study 1, PLTs suspended in 5% plasma/95% PAS‐5 were prepared directly on a separator (Amicus, Fenwal, Inc.) without additional centrifugation or washing. In Study 2, a double unit of hyperconcentrated Amicus PLTs in plasma was collected, divided, and centrifuged to prepare a control unit in 100% plasma and a paired test unit in 5% plasma/95% PAS‐5. The in vitro properties of PLTs were assessed in both studies during 7‐day storage at 20 to 24°C with continuous agitation. RESULTS: In Study 1, PLT concentration, pH, mean PLT volume (MPV), HCO₃^‐, pCO₂, pO₂, lactate dehydrogenase, and hypotonic shock response (HSR) did not significantly change during storage. By Day 7, glucose levels and morphology scores modestly decreased (17.6 and 14.4%, respectively) and lactate levels modestly increased (to 7.2 mmol/L). In Study 2, MPV, pH, glucose, pO₂, HSR, and morphology were comparable in control and test PLTs during 7‐day storage. Glucose consumption and lactate production were significantly less in test versus control PLTs (p ≤ 0.0015). Extent of shape change and %CD62P‐positive test PLTs were less than those of controls (p < 0.001). CONCLUSION: Apheresis PLTs suspended in 5% plasma/95% PAS‐5 maintained in vitro properties during 7‐day storage.     

Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage

BACKGROUND: Stress-enhanced platelet (PLT) storage lesions include increased glycolysis, discoid-to-sphere morphology change, and spontaneous PLT activation. It is not clear if reduction in glycolysis can alleviate storage lesion development. STUDY DESIGN AND METHODS: Apheresis PLT concentrates were exposed to 17.2 J/mL UV light and 50 microM riboflavin, followed by storage with various concentrations of 2-deoxyglucose (2-DOG) for 5 days. The control had no UV or 2-DOG exposure. RESULTS: Lactate production and glucose consumption were increased significantly to 0.1371 +/- 0.0281 and 0.0724 +/- 0.0151 mmol per 10(12) cells per hour for UV-treated PLTs, respectively, when compared to control samples. UV treatment induced a decline in pH to 6.55 +/- 0.26 for treated PLTs on Day 5, hypotonic shock response (HSR) 33 +/- 25 percent, extent of shape change (ESC) to 3.8 +/- 3.6 percent, swirl 1.0 +/- 1.0 and increased P-selectin expression 85.2 +/- 9.4 percent. Addition of 2-DOG up to 20 mmol per L significantly reduced lactate production to 0.0515 +/- 0.0045 mmol per 10(12) cells per hour (p < 0.05) and glucose consumption to 0.0293 +/- 0.0060 mmol per 10(12) cells per hour and increased pH to 7.35 +/- 0.09 in a dose-dependent manner. 2-DOG, however, had no effects on HSR, ESC, swirl, and P-selectin expression. Furthermore, an exaggeration of UV-stressed PLT aggregation by addition of 2-DOG was also observed. CONCLUSIONS: Increased glycolytic flux is not a direct cause for PLT morphology change and spontaneous activation during storage lesion development. Reduction of glucose utilization may increase PLT loss during storage.     

Effects of immediate or delayed addition of platelet additive solution on the in vitro quality of apheresis platelets

BACKGROUND: There is little knowledge how different hold times of hyperconcentrated platelet (PLT) suspensions (HPSs) before the addition of platelet additive solution (PAS) might affect PLT quality. We compared the in vitro quality of single‐donor PLT concentrates (SDPs) with immediate or delayed PAS addition and studied the quality of collected concurrent plasma (CP). STUDY DESIGN AND METHODS: We collected 6 × 10¹¹ PLTs in 175 of mL plasma and CP from 31 donors. The HPSs were split into two parts, with 162 mL of modified PAS III (PAS‐IIIM) added immediately (0hr‐SDP) or 2 hours later (2hr‐SDP). Final SDPs had a targeted concentration of 1.2 × 10¹² PLTs/L and a PAS proportion of 65%. On Days 1, 5, and 7 we determined glucose and lactate concentration, pH, P‐selectin expression, hypotonic shock response (HSR), and extent of shape change (ESC). Clotting Factor V (FV) and VIII (FVIII) activities and D‐dimer concentration were determined in CP and donor. RESULTS: Glucose utilization, lactate production, and pH were similar for both kinds of products. Low P‐selectin expression indicated no relevant PLT activation during storage. HSR and ESC were similarly well preserved. Recoveries of FV and FVIII were 100.0 ± 14.0 and 98.6 ± 14.9%, respectively. Concentrations of D‐dimers in the donor and CP were 173.7 ± 90.1 and 177.6 ± 91.2 ng/dL, respectively. CONCLUSIONS: Adding PAS immediately or 2 hours after collection does not result in different in vitro quality of PLTs stored up to 7 days. The good recovery of clotting factors with no signs of activation indicates a good quality of CP.     

小儿重症肺炎血小板参数的动态变化分析

目的:探讨重症肺炎患儿血小板参数动态变化。方法:动态测定38例重症肺炎患儿(A组)的血小板参数包括血小板计数(PLT)、血小板分布宽度(PDW)、平均血小板容积(MPV)及大血小板比率(P-LCR),同时与普通肺炎患儿80例(B组)和正常儿童(C组)100例作对照。结果:入院24h内A组PLT明显高于B、C组,均P<0.01,而PDM、MPV、P-LCR低于C组,差异有显著性,P<0.05;B组PLT高于C组,P<0.05,而PDW、MPV、P-LCR与C组比较无差异,P>0.05。入院72h后复查,B组各血小板参数基本恢复正常,与C组比较无差异,P>0.05;A组PLT明显下降,而PDM、MPV、P-LCR明显升高,与C组比较有显著性差异,P<0.05;入院第7d复查,各参数基本恢复正常。结论:动态检测肺炎患儿的血小板参数有助于准确评估病情的危重度。     

Comparative in vitro evaluation of apheresis platelets stored with 100% plasma versus bicarbonated Ringer's solution with less than 5% plasma

BACKGROUND: The major strategy for reducing the frequency of adverse reactions to platelet (PLT) transfusions is PLT washing with PLT additive solutions (PASs). In Japan, a mixture of medical infusion solutions such as acetate Ringer's solution, sodium bicarbonate, magnesium sulfate, and ACD‐A is currently used as a PAS because none of the common types of PASs are officially permitted for clinical use. Recently, a bicarbonated Ringer's solution (BRS) was developed using bicarbonate as an alkaline agent. The aim of this study was to evaluate whether a BRS can effectively be utilized as a PAS for clinical use. STUDY DESIGN AND METHODS: The washing and storage solution was prepared by adding 25 mL ACD‐A to 500 mL of BRS (BRS‐A), consisting of 95.2 mmol/L NaCl, 3.8 mmol/L KCl, 0.9 mmol/L MgCl₂,1.4 mmol/L CaCl₂, 26.6 mmol/L NaHCO₃, 5.8 mmol/L glucose, 4.2 mmol/L trisodium citrate, and 1.8 mmol/L citric acid. The in vitro properties of apheresis PLTs suspended in BRS‐A with low concentration of plasma (<5%) were compared with those suspended in 100% plasma during 7‐day storage. RESULTS: The in vitro properties of pH, hypotonic shock response, glucose consumption rate, lactate production rate, swirling, CD62P, and CD42b expression in PLTs suspended in BRS‐A were comparable or superior to those suspended in 100% plasma during 7‐day storage. CONCLUSION: BRS‐A, prepared by mixing the only two solutions permitted for clinical use in Japan, has a positive capability to maintain PLT function. These results indicate that PLT washing and storage with BRS‐A is feasible.     

Soluble glycoprotein V as a quality marker of platelet concentrates stressed by transportation

BACKGROUND: Despite ongoing improvements in storage conditions for platelet concentrates (PCs) for clinical use, leukoreduced platelets (PLTs) undergo subtle changes that are partly due to PLT activation. As PLTs are activated, the expression of P-selectin (CD62P) increases, and soluble glycoprotein V (sGPV) is released. GPV, part of the GPIbIXV complex, has been suggested as a marker of PLT activation. STUDY DESIGN AND METHODS: An array of assays, used for quality control of PCs, was performed and the results were compared. The tests included PLT count, swirling, mean PLT volume, extent of shape change (ESC), hypotonic shock response (HSR), CD62P, lysosomal membrane protein (CD63), sGPV, and the metabolic tests (pH, pO(2), pCO(2), lactate, glucose). The performance of the assays was evaluated during the storage period by comparing buffy coat-derived PCs (24 PCs of 4 units) stored on flatbed agitator or stressed twice by overnight transportation. RESULTS: The repeatability of all tests was good. ESC and HSR correlated with each other (r = 0.559). Importantly, there were also associations between sGPV and ESC (r = -0.564) and HSR (r = -0.389). The correlations of sGPV with lactate and glucose concentrations and with expression of CD62P and CD63 were also good. No significant changes were induced by two overnight transportations. CONCLUSION: sGPV might be applicable for statistical process control of the quality of PCs, in addition to metabolic tests. It may also be helpful in analyzing potential improvements in blood component processing. Repeat transportation of PCs may cause minimal changes on PLT in vitro properties, if any.     

血小板体积及分布宽度检测儿童川崎病价值

目的 平均血小板体积(MPV)与血小板分布宽度(PDW)与血小板功能有关,相比血小板数量可能更能成为血小板功能异常的敏感指标。研究血小板参数在川崎病中的变化及临床意义。方法 本研究共回顾性分析439例KD患儿和261例健康对照儿童;统计分析患儿的临床资料及实验室检查MPV、PDW、血小板数量(PLT)、WBC、CRP和血沉指标。根据心脏彩色超声有无冠状动脉损伤,将川崎病患儿分为:伴冠状动脉损伤组(CALs组)、不伴冠状动脉损伤组(非CALs组)。同时,比较了完全性川崎病组(cKD)与不完全川崎病组(iKD)各指标的差异。结果 与健康对照组比较,KD组WBC、PLT、CRP和ESR水平显著升高(P<0.01),而MPV与PDW明显下降(P<0.01,<0.05);尤其相比于cKD组,MPV与PDW水平在iKD组明显降低(P=0.003、0.014)。结论 提示川崎病患儿急性期MPV与PDW降低,尤其在不完全川崎病降低显著,故低水平的MPV与PDW可能对iKD的诊断有提示意义。     

In vitro properties of apheresis platelet during extended storage in plasma treated with anandamide

BackgroundIn China apheresis platelets (PLTs) are stored in plasma for only 5 days, resulting in PLT inventory pressures. Anandamide (ANA) was reported to be a potential agent to inhibit PLT apoptosis. The aim of this study was to evaluate the characteristics of extended storage PLTs in plasma treated with ANA in vitro.MethodsApheresis PLTs (n = 20) were prepared in plasma treated with ANA, and stored at 22 °C for up to 11 days. On day 1, 3, 5, 7, 9 and 11, PLTs were tested for PLT count, mean PLT volume (MPV), PLT distribution width (PDW), pH, pCO₂, pO₂, hypotonic shock response (HSR), phosphatidylserine (PS) exposure and soluble P-selectin content.ResultsPLTs stored in plasma with/without ANA didn't show significant differences during the first 5 days of storage. From the 7^th day on, PLTs stored in plasma with ANA displayed significantly lower PS expression, soluble P-selectin content and higher HSR scores than those stored in plasma without ANA (P <0.05), respectively.ConclusionThe extended storage of PLTs in plasma treated with 0.5 µmol/l ANA showed better characteristics of the PLTs, compared with the control group, which was suggested to potentially alleviate the PLT storage lesion.